Find verified Zadavotide guraxetan API manufacturers, suppliers, and distributors across the globe. Explore companies that offer high-purity Zadavotide guraxetan for pharmaceutical use, along with product details, certifications, and reliable sourcing options. Compare prices, check availability, and connect directly with trusted suppliers for Zadavotide guraxetan API.
Alternate Names: PSMA inhibitor for imaging and therapy
CAS No: 2192281-54-0
PubChem CID: 156596528
Mol Formula: C63H92IN11O23
Mol Weight: 1498.4 g/mol
IUPAC Name: (2S)-2-[[(1S)-1-carboxy-5-[[8-[[(5R)-5-carboxy-5-[[(2R)-2-[[(2R)-2-[[(4R)-4-carboxy-4-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]buta -Show More
API Description: Zadavotide Guraxetan (also known as Lutetium‑177 Zadavotide Guraxetan, PSMA I&T, or PNT‑2002) is a targeted radioligand therapy agent under investigation for prostate cancer treatment. It combines a small molecule that binds specifically to the prostate‑specific membrane antigen (PSMA) — which is overexpressed on many prostate cancer cells — with the radioisotope lutetium‑177. When the compound attaches to PSMA‑expressing tumor cells, lutetium‑177 emits beta radiation locally, damaging the cancer cells while minimizing effects on surrounding healthy tissue. Clinical trials (Phase I/II) are underway, exploring its safety, tolerability, and effectiveness in patients with recurrent or metastatic prostate cancer.
